KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Invested Capital: 2010-2025

Historic Invested Capital for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $85.1 million.

  • Nektar Therapeutics' Invested Capital rose 74.06% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 74.06%. This contributed to the annual value of $60.7 million for FY2024, which is 53.63% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Invested Capital stood at $85.1 million, which was up 451.44% from -$24.2 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Invested Capital ranged from a high of $994.5 million in Q1 2021 and a low of -$24.2 million during Q2 2025.
  • In the last 3 years, Nektar Therapeutics' Invested Capital had a median value of $85.1 million in 2025 and averaged $101.7 million.
  • Over the last 5 years, Nektar Therapeutics' Invested Capital had its largest YoY gain of 74.06% in 2025, and its largest YoY loss of 130.38% in 2025.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Invested Capital stood at $679.5 million in 2021, then crashed by 46.04% to $366.6 million in 2022, then crashed by 64.27% to $131.0 million in 2023, then plummeted by 53.63% to $60.7 million in 2024, then surged by 74.06% to $85.1 million in 2025.
  • Its last three reported values are $85.1 million in Q3 2025, -$24.2 million for Q2 2025, and $13.7 million during Q1 2025.